• Users Online: 769
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2018  |  Volume : 46  |  Issue : 2  |  Page : 139-144

Serum galectin-9 level in patients with atopic dermatitis

1 Department of Dermatology and Venereology, Tanta University Hospital, Tanta, Egypt
2 Department of Clinical Pathology, Tanta University Hospital, Tanta, Egypt
3 Department of Dermatology and Venerology, Kafr Elsheikh Dermatology Hospital, Tanta, Egypt

Correspondence Address:
Shaimaa E Elgedawy
Mahallet Ziad, Samannoud, Gharbia Governorate, 31816
Login to access the Email id

DOI: 10.4103/tmj.tmj_71_17

Rights and Permissions

Background Atopic dermatitis (AD) is a common chronic inflammatory skin disease of unknown etiology. It is characterized by peripheral eosinophilia, mast cell activation, and predominance of T-helper-2 cells. Galectin-9 is a potent eosinophilic chemoattractant. It also alters T-cell balance by negatively regulating T-helper cells, resulting in T-helper-2 polarization. Inhibition of endogenous galectin-9 may improve the course of the disease. Aim The aim of this study was to evaluate serum level of galectin-9 in patients with AD to assess its possible role in pathogenesis of the disease. Patients and methods The current study included 20 patients with AD and 10 age-matched and sex-matched healthy individuals who served as a control group. Patients were divided into three groups, mild, moderate, and severe, according to their Six-Area, Six-Sign Atopic Dermatitis score. Peripheral venous blood sample was taken from each participant, and serum was examined by enzyme-linked immunosorbent assay for quantitative evaluation of galectin-9. Results Galectin-9 was significantly increased in patients with AD compared with the control group. The difference between the three studied groups was statistically significant regarding serum galectin-9 level. There was significant positive correlation between serum galectin-9 level and severity of the disease. In contrast, no significant correlations were found between serum galectin-9 level and age, sex of the patients, and duration of the disease. Conclusion Serum galectin-9 level was significantly elevated in patients with AD. This increase was positively correlated with disease severity. This suggests a possible role of galectin-9 in the pathogenesis of AD. New treatment strategies that are directed toward lowering galectin-9 level may be a hope for future perspectives of the treatment of AD.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal